Supreet Agarwal

Scientist, NCI/ NIH, Prostate Cancer

[Supreet Agarwal @SupreetAg01]

@EtihadHelp And this is the response I get from the agent.

tried emailing and got the following response "Dear Guest, Please be advised that the email address that you have used to contact us is not active for the purpose of filing cases or inquiries.
"
What a joke! @etihad @EtihadHelp

[Supreet Agarwal @SupreetAg01]

Flew business class with @etihad recently – damaged my multiple bags – Asked for endless documents – Then refused responsibility
Etihad sells “premium service” but delivers premium negligence.
If this is how they treat business class passengers, think twice before booking.

[Supreet Agarwal @SupreetAg01]

@etihad Flew business class with @etihad recently
– damaged my multiple bags
– Asked for endless documents
– Then refused responsibility
Etihad sells “premium service” but delivers premium negligence.
If this is how they treat business class passengers, think twice before booking.

[Cancer_Evolve @cancer_evolve]

DRUG TARGETS: biomarkers of efficacy for ADCs have historically focussed only on expression of the antibody target; preclinical studies have identified genomic biomarkers of response/resistance reflecting sensitivity to the payload.
https://t.co/6WFZ3RdHbk

[Daniel E. Frigo, Ph.D. @DanielFrigo]

Despite what you may have heard, the #androgenreceptor is still a big deal in #prostatecancer. But how we target AR is evolving. Join us Jan 16 for a free @TheEndoSociety webinar with an expert panel to discuss new trends in anti-AR therapy. Registration👉https://t.co/4MAtiuunk7

[Paolo Tarantino @PTarantinoMD]

Correct! Anthracyclines were originally discovered in Italy approximately 70 years ago by a company named Farmitalia.

A member of the team went on expedition to Castel del Monte, in Puglia, in which soil he identified a strain of Streptomyces producing a substance with antitumoral proprieties: he called it “Daunomycin”, from the tribes of “Daunii” that used to live in Puglia during the Bronze Age.

The first trials with daunomycin were conducted at the NCI of Milan and at MSKCC, describing the first clinical responses. Meanwhile, the team at Farmitalia kept working on the molecule, developing an even more potent analogue.

They called it “Adriamycin”, from the Adriatic Sea that bathes the shores of Puglia, and that can be easily reached from Castel del Monte, where everything started.

More info here: https://t.co/UgQujAnGnX

[Eytan Ruppin, MD, PhD @EytanRuppin]

Are #cancers more like their normal origin or target tissues in #metastasis? Our recent work, now on bioRxiv, systematically compares the #transcriptomics of primary and metastatic #tumors to healthy tissues in a #PanCancer, genome-wide manner. (1/9) https://t.co/l1i57vp9X3

[Neeraj Agarwal, MD, FASCO @neerajaiims]

#ESMO23 Fantastic and insightful presidential session discussion by @apolo_andrea on two practice changing presentations 👉wonderful news which bring up new questions and challenges 👇@OncoAlert @urotoday @Uromigos @BladderCancerUS Congratulations Andrea!!

[Paolo Tarantino @PTarantinoMD]

I’ve learned a lot from this collaborative effort, and I can’t thank enough @BiagioRicciutMD, Shan Pradhan from @FDAOncology & @stolaney1 for contribution, @Raffaele_1985 for precious insights and Peter Sidaway for the incredible editorial support!
https://t.co/QcpeKTosCq

[Leena Latonen @LatonenLeena]

@slavov_n @Varjosalo_Lab In cancer, so many - here’s our example in #prostatecancer showing that mRNA-protein correlations at the proteome level get worse when disease progresses. Translational control is so much more important in also cancer than currently given credit for. https://t.co/7nxmAPSP8T

[Kathleen Helen Burns @KathleenHBurns]

Excited to share that LINE-1-encoded ORF1p, our "hallmark of cancer" is detectable in the peripheral blood. 🩸 A brilliant collaboration with the Walt lab @wyssinstitute @BWHPath and many generous colleagues @MGHCancerCenter @DanaFarber. https://t.co/5Sy5KXKc8J

[Andy Minn @andyjminn]

A lot of perplexing data showing chronic interferon (IFN) promotes immunotherapy resistance. But why is chronic IFN different from acute, which clearly is important for response? New paper by @jingya & Bihui Xu shows one reason: inflammatory memory! (1/n) https://t.co/shlhQKr0Pf

[Paolo Tarantino @PTarantinoMD]

Make sure not to miss the #SABCS22 session on #HER2low BC, featuring:
-🥊 a boxing session on HER2-low by my awesome mentors @stolaney1 & @curijoey
-our HER2-low NGS data from >1000 pts treated at DFCI
-biomarker data from DB-04 by @prat_aleix
-much more!
https://t.co/aWur4nOmTj

[Paolo Tarantino @PTarantinoMD]

HER2-low: not only a breast cancer story. In this phase 2 trial enrolling patients with pretreated, HER2-low gastric/GEJ cancer, T-DXd (6.4 mg/kg) achieved an ORR of 26% in 2+ and 9.5% in 1+. Far from the DB-04 activity, but pretty intriguing nonetheless.
https://t.co/kPxNfVrGpb

[Paolo Tarantino @PTarantinoMD]

The mysteries of ADCs: do they work the way we believe they do? Interesting editorial by @Dereklowe on one of the most successful anti-cancer drug classes, for which still a lot remains to be understood.
https://t.co/0H2excV5CK

[Supreet Agarwal @SupreetAg01]

@PTarantinoMD Great points! Underlying tumor biology likely potentiates the payload activity, irrespective of the target antigen level, which is probably what is being seen in patients. We proposed this for a different ADC - https://t.co/MgGjnRZHmk
Having hard time to convince reviewers :)

[Paolo Tarantino @PTarantinoMD]

T-DXd has shown remarkable activity for treating HER2-positive and HER2-low breast cancers.

However, it may soon expand its reach, and become a treatment option even for HER2-0 tumors.

Here’s the 10 reasons why:

[Salma Kaochar @Kaochar2]

Truly love this thread.

[Supreet Agarwal @SupreetAg01]

@PingMu_PhD Perhaps time for a mini-symposium on IFN signaling in prostate cancer to brainstorm effective translation of these observations in clinic :P

[Supreet Agarwal @SupreetAg01]

@PingMu_PhD Nice to see growing evidences in support of important role of IFN/JAK/STAT signaling in prostate cancer. I presented some of our initial findings in 2017 at AACR (https://t.co/hivxs4vbS8). The textbook JAK/STAT pathway looks straightforward but is super-complex.